Amendments to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

1-15. (Cancelled)

16. (Currently amended) A compound of formula (1):

wherein

is a single bond;

A is phenylene:

n is 1:

R1 is hydrogen;

R2 is hydrogen:

 R^3 is selected from $C_{1:4}$ alkyl optionally substituted by 1 or 2 hydroxy groups provided that when there are 2 hydroxy groups they are not substituents on the same carbon, cvano $C_{1:4}$ alkyl, and $C_{1:4}$ alkyl substituted by 1 or 2 R^8 groups provided that when there are 2 R^8 groups they are not substituents on the same carbon:

R⁸ is independently selected from hydroxy, heterocyclyl, C₁₋₄alkanoyl, C₁₋₄alkoxy, C₁₋₄alkanesulfinyl, C₁₋₄alkanesulfonyl, -COCOOR⁹, (R⁹)(R¹⁰)NCO-, -COCH₂OR¹¹, (R⁹)(R¹⁰)N-, -COOR⁹ and 2.2-dimethyl-1.3-dioxolan-4-vl:

 R^9 and R^{10} are independently selected from hydrogen, hydroxy, $C_{1:3}$ alkyl optionally substituted by 1 or 2 hydroxy groups provided that when there are 2 hydroxy groups they are not substituents on the same carbon and $C_{1:3}$ alkyl substituted by $C_{1:3}$ alkoxy and wherein R^9 and R^{10} can together with the nitrogen to which they are attached form 4- to 6-membered ring where the ring is optionally substituted on carbon by 1 or 2 substituents selected from hydroxy or carboxy;

R¹¹ is selected from hydrogen, C₁₋₄alkyl, C₁₋₄alkoxy and hydroxyC₁₋₄alkyl; m is 1:

Application No.
Amendment Dated
Reply to Office Action of

10/506,748 09/18/2006 05/22/2006

R⁴ is chloro;

is a single or double bond;

A is phenylene or heteroarylene;

m is 1:

n is 0, 1, or 2;

 $R^{4}\ \ is\ independently\ selected\ from\ halo,\ nitro,\ cyano,\ hydroxy,\ carbaxy,\ carbamoyl,\ N-N-(C_{1-a}lkylcarbamoyl,\ N-N-(C_{1-a}lkylcarbamoyl,\ N-N-(C_{1-a}lkylcarbamoyl,\ N-N-(C_{1-a}lkylcarbamoyl,\ N-N-(C_{1-a}lkylcarbamoyl,\ N-N-(C_{1-a}lkylcarbamoyl,\ N-N-(C_{1-a}lkylcarbamoyl,\ C_{1-a}lkylcarbamoyl,\ N-N-(C_{1-a}lkylcarbamoyl,\ N-N-(C_{1-a}lkylcarbamoyl,\ N-N-(C_{1-a}lkylcarbamoyl,\ N-N-(C_{1-a}lkanoyl),\ N-N-(C_{1-a}lkylcarbamoyl,\ N-N-(C_{1-a}lkylcarbamo$

when n is 2, the two R⁴ groups, together with the carbon atoms of A to which they are attached, may form a 4- to 7-membered ring, optionally containing 1-or 2-heteroatoms independently selected from O, S, and N, and optionally being substituted with one or two methyl groups; R⁴ is chlore:

R2 is hydrogen, hydroxy, or carboxy;

 \mathbb{R}^3 is selected from hydrogen, hydroxy, $\mathbb{C}_{1,4}$ alkoxy, $\mathbb{C}_{1,4}$ alkaneyl, carbameyl, $\mathbb{C}_{2,7}$ eycloalkyl (optionally substituted with 1 or 2 hydroxy groups), eyano($\mathbb{C}_{1,4}$ alkyl, aryl, heterocyclyl, $\mathbb{C}_{1,4}$ alkyl (optionally substituted with 1 or 2 \mathbb{R}^8 groups), and groups of the formulae B and B'

wherein v is 0 or 1, t is 0, 1, 2, or 3 and u is 1 or 2;

provided that the hydroxy group is not a substituent on the ring carbon adjacent to the ring exygen;

R⁸ is independently selected from hydroxy, G_{1.4}alkoxyG_{1.4}alkoxy, hydroxyG_{1.4}alkoxy, 5- and 6-membered syclic acetals and meno- and di-methyl-derivatives thereof, and, heterocyclyl, G_{2.7}eyclealkyl, G_{1.4}alkanoyl, C_{1.4}alkoxy, G_{1.4}alkylS(O)_b- (wherein b is 0, 1, or 2), G_{2.6}cyclealkylS(O)_b- (wherein b is 0, 1, or 2), heterocyclylS(O)_b- (wherein b is 0, 1, or 2), heterocyclylS(O)_b- (wherein b is 0, 1, or 2), henzylS(O)_b- (wherein b is 0, 1, or 2). N(OH)CHO, G(=NOH)NH_{2.-}C(=NOH)NHC_{1.4}alkyl, C(=NOH)NHG_{1.4}alkyl, C(=NOH)NHG_{1.4}alkoxy, hydroxyge_{1.4}alkoxy, hydroxyge_{1.4}alkoxyge

10/506,748 09/18/2006 05/22/2006

 $\label{eq:condition} $$-C(-N-OH)N(G_{a,6}\text{syclealkyH})_{a}$-COCOOR^6,-C(O)N(R^6)(R^{10}),-NHC(O)R^9,-C(O)NHSO_{\mathcal{E}}(G_{1,4}\text{alkyH}),-NHSO_{\mathcal{E}}R^9,(R^9)R^{10})NSO_{\mathcal{E}},-COCH_2OR^{11},(R^9)(R^{10})N_{1,4}\text{and}-COOR^9;$

 R^{9} and R^{19} are independently selected from hydrogen, hydroxy, $C_{4,4}$ alkyl (optionally substituted with 1 or 2 hydroxy groups),

 $cyano(C_{1\!-\!4})alkyl,\ trihalo(C_{1\!-\!4})alkyl,\ aryl,\ heterocyclyl,\ and\ heterocyclyl(C_{1\!-\!4}alkyl);\ or$

 R^{9} and R^{10} together with the nitrogen to which they are attached form a 4- to 6-membered ring where the ring is optionally substituted on carbon with 1 or 2-substituents independently selected from exe, hydroxy, carboxy, hale, nitre, cyane, carbonyl, $C_{1,4}$ alkexy, and heterocyclyl, or the ring may be optionally substituted on two adjacent carbons with -0 CH₂ -0 to form a cyclic acetal wherein one or both of the hydrogens of the -0 CH₂ -0 group may be replaced by a methyl; R^{13} is selected from hydroxy, hale, trihalomethyl, and $C_{1,4}$ alkexy; and R^{14} is independently selected from hydrogen, $C_{1,4}$ alkyl, and hydroxy $C_{1,4}$ alkyl; or a pharmaceutically acceptable salt or prodrug thereof.

17-22. (Cancelled)

23. (Currently amended) A compound of claim 16 selected from:

5-chloro-*N*-[1-(methoxycarbonylmethyl)-2-oxo-1,2,3,4-tetrahydroquinolin-3-yl]-1*H*-indole-2-carboxamide:

N-[1-(carboxymethyl)-2-oxo-1,2,3,4-tetrahydroquinolin-3-yl]-5-chloroindole-2-carboxamide; and 5-chloro-N-(2-oxo-1,2,3,4-tetrahydroquinolin-3-yl)-1H-indole-2-carboxamide;

5-chloro-N-[{2-oxo-1-[2-oxo-2-(pyridin-2-ylamino)ethyl]-1,2,3,4-tetrahydroquinolin-3-yl}-1H-indole-2-carboxamide:

5-chloro N [1-[2-(methylthio)ethyl] 2-exo-1,2,3,4-tetrahydroquinolin 3-yl}-1H-indole-2-carboxamide:

5-chloro-N {1-[2-(methylsulphinyl)ethyl]-2-oxo-1,2,3,4-tetrahydroquinolin-3-yl}-1H-indole-2-carboxamide:

5-chloro-N-(1-[2-(methylsulphonyl)ethyl]-2-oxo-1,2,3,4-tetrahydroquinolin-3-yl)-1/L-indole-2-carboxamide;

5-chlore-N-(2-oxo-1-[2-oxo-2-(1,3,4-thiadiazol-2-ylamino)ethyl]-1,2,3,4-tetrahydroquinolin-3-yl]1H-indole-2-carboxamide:

5-chloro-N-(1-{2-{(6-methylpyridin-2-yl)amino}-2-oxoethyl}-2-oxo-1,2,3,4-tetrahydroquinolin-3-yl}-1H-indole-2-carboxamide;

Application No. 10/506,748
Amendment Dated 09/18/2006
Reply to Office Action of 05/22/2006

5-chloro-*N*-(2-oxo-1-[2-oxo-2-(pyridin-3-ylamino)ethyl]-1,2,3,4-tetrahydroquinolin-3-yl]-1*H*-indole-2-carboxamide:

5-chloro-N-(1-{2-[(5-methyl-1,3,4-thiadiazol-2-yl)aminol-2-oxoethyl}-2-oxo-1,2,3,4-

tetrahydroguinolin-3-yl)-1H-indole-2-carboxamide;

5-chloro-N-(1-{2-{(5-ethyl-1,3,4-thiadiazol-2-yl)aminol-2-oxoethyl}-2-oxo-1,2,3,4-

tetrahydroguinolin-3-vl)-1H-indole-2-carboxamide:

5-chloro N (1-[2-[(4-cyano-1H-pyrazol-3-yl)amino]-2-exeethyl]-2-exe-1,2,3,4-tetrahydroquinolin-3-yl)-1H-indole-2-carboxamide:

5-chloro-*N* (1-[2-[(4-methyl-1,3-thiazel-2-yl)amino]-2-oxoethyl]-2-oxo-1,2,3,4-tetrahydroquinolin-3-yl)-1/H-indole-2-carboxamide;

5-chlore N (1-[2-[(6-chlorepyridin-3-yl)amino]-2-exeethyl]-2-exe-1,2,3,4-tetrahydroquinolin-3-yl)-1H-indole-2-carboxamide:

5-chlore-N-(1-[2-[(3-hydroxypyridin-2-yl)amino]-2-oxoethyl]-2-oxo-1,2,3,4-tetrahydroquinolin-3-yl)-1H-indole-2-carboxamide:

5-chloro-N-(2-oxo-1-{2-oxo-2-{(pyridin-2-ylmethyl)amino]ethyl}-1,2,3,4-tetrahydroquinolin-3-yl}-1H-indole-2-carboxamide:

5-chloro-N-{2-oxo-1-{2-oxo-2-(pyridin-4-ylamino)ethyl}-1,2,3,4-tetrahydroquinolin-3-yl}-1*H*-indole-2-carboxamide;

5-chloro-N-(1-{2-{(1-methyl-1H-pyrazol-5-yl)amino}-2-oxoethyl}-2-oxo-1,2,3,4-tetrahydroquinolin-3-yl}-1H-indolo-2-carboxamide:

 $\hbox{5-chloro-$N$-(1-{2-[(1,3-dimethyl-1$H-pyrazol-5-yl)amino}]-2-oxoethyl}-2-oxo-1,2,3,4-$

tetrahydroquinolin-3-yl)-1H-indole-2-carboxamide;

5-chloro-N-(2-oxo-1-{2-oxo-2-{(pyrazin-2-ylmethyl)amino]othyl}-1,2,3,4-tetrahydroquinolin-3-yl}-4H-indole-2-carboxamide:

5-chlore N (1-[2-[(6-fluoropyridin-3-yl)amino]-2-oxoethyl]-2-oxo-1,2,3,4-tetrahydroquinolin-3-yl)-1H-indole-2-carboxamide:

5-chlore N (1-{2-{(2-hydroxypyrimidin 4 yl)amino} 2-oxoethyl} 2-oxo 1,2,3,4-tetrahydroquinolin-3-yl) 1H-indole 2-carboxamide:

5-chloro-N-{2-oxo-1-[2-oxo-2-(pyrimidin-4-ylamino)ethyl]-1,2,3,4-tetrahydroquinolin-3-yl}-1H-indole-2-carboxamide:

5-chloro-N (1-[2-[(1-ethyl-1H-pyrazol-5-yl)amino]-2-exoethyl]-2-exo-1,2,3,4-tetrahydroquinolin-3-yl)-1H-indolo-2-carboxamide;

5-chlore-N-(2-oxo-1-{2-oxo-2-{(5-oxo-4,5-dihydro-1H-pyrazol-3-yl)amino]ethyl}-1,2,3,4-tetrahydroquinolin-3-yl)-1H-indole-2-carboxamide;

5-chloro-N-(1-[2-[(4-hydroxypyrimidin-2-yl)amino]-2-oxoethyl]-2-oxo-1,2,3,4-tetrahydroquinolin-3-yl)-1H-indole-2-carboxamide;

5-chloro-N-(1-[2-[(3-methylpyridin-2-yl)amino]-2-oxoethyl}-2-oxo-1,2,3,4-tetrahydroquinolin-3-yl)-1H-indole-2-carboxamide:

5-chloro-*N*-(1-[2-[(6-chloropyridazin-3-yl)amino]-2-oxoethyl]-2-oxo-1,2,3,4-tetrahydroquinolin-3-yl) 1*H* indole 2-carboxamide:

5-chloro N (1-{2-{(1H-imidazol-2-ylmethyl)amino} 2-exeethyl} 2-exe-1,2,3,4-tetrahydroquinolin-3-yl) 1H-indole 2-carboxamide:

6-chloro-N-(1-[2-[(1-methyl-1H-pyrazol-3-yl)amino]-2-oxoethyl]-2-oxo-1,2,3,4-tetrahydroquinolin-3-yl)-1H-indole-2-carboxamide;

5-chloro-N-{2-oxo-1-{2-oxo-2-(2H-tetrazol-5-ylamino)ethyl]-1,2,3,4-tetrahydroquinolin-3-yl]-1H-indole-2-carboxamide:

5-chlore-N-(1-[2-[(3-ethyl-1H-pyrazol-5-yl)amino]-2-excethyl]-2-exe-1,2,3,4-tetrahydroquinolin-3-yl)-1H-indole-2-carbexamide:

5-chloro-N-(1-{2-[(5-fluoropyridin-2-yl)amino}-2-exeethyl}-2-exe-1,2,3,4-tetrahydroquinolin-3-yl)-1H-indole-2-carboxamide:

W-(1-[2-[(6-bromopyridin-3-yl)amino]-2-oxoethyl]-2-oxo-1,2,3,4-tetrahydroquinolin-3-yl)-5-chloro-1-W-indole-2-carboxamide:

5-chloro-N-[1-(2-hydroxyethyl)-2-oxo-1,2,3,4-tetrahydroquinolin-3-yl]-1H-indole-2-carboxamide; 5-chloro-N-{1-{(2,2-dimethyl-1,3-dioxan-5-yl)methyl]-2-oxo-1,2,3,4-tetrahydroquinolin-3-yl]-1H-indole-2-carboxamide;

5-chlore-N-{1-[3-hydroxy-2-(hydroxymethyl)propyl]-2-oxo-1,2,3,4-tetrahydroquinolin-3-yl]-1H-indole-2-carboxamide:

5-chloro N [1 (2,3-dihydroxypropyl) 2-oxo-1,2,3,4-tetrahydroquinolin-3-yl]-1H-indole-2-earboxamide:

5-chloro-W [1 (3-hydroxy-2-exepropyl) 2-exe-1,2,3,4-tetrahydroquinolin-3-yl] 1H-indole-2-earbexamide:

5-chloro-N-{1-[(2R)-2,3-dihydroxypropyl]-2-oxo-1,2,3,4-tetrahydroquinolin-3-yl]-1H-indole-2-carboxamide:

5-chlore-N-(1-[2-[(methylsulfonyl)amino]ethyl]-2-oxe-1,2,3,4-tetrahydroquinolin-3-yl)-1H-indole-2-carboxamide:

N-{1-[2-(acetylamino)ethyl]-2-oxo-1,2,3,4-tetrahydroquinolin-3-yl]-5-chloro-1*H*-indole-2-carboxamide;

5-chlore-N-(2-oxe-1-{2-{(trifluoroacetyl)amino]ethyl}-1,2,3,4-tetrahydroquinolin-3-yl)-1H-indole-2-carboxamide:

5-chloro-N-[1-(3-hydroxypropyl)-2-oxo-1,2,3,4-tetrahydroquinolin-3-yl]-1H-indole-2-carboxamide; N-(1-[(2Z)-2-amino-2-(hydroxyimino)ethyl]-2-oxo-1,2,3,4-tetrahydroquinolin-3-yl]-5-chloro-1Hindole-2-carboxamide;

5-chloro-*N*-(6-fluoro-2-oxo-1,2,3,4-tetrahydroquinolin-3-yl)-1*H*-indole-2-carbexamide; and 5-chloro-*N*-[6-(methyloxy)-2-oxo-1,2,3,4-tetrahydroquinolin-3-yl]-1*H*-indole-2-carbexamide; or a pharmaceutically acceptable salt or an in-vivo hydrolysable ester thereof.

24. (Previously Presented) A pharmaceutical composition which comprises a compound of claim 16, or a pharmaceutically acceptable salt or in-vivo hydrolysable ester thereof, in association with a pharmaceutically acceptable diluent or carrier.

25 - 26. (Cancelled)

27. (Previously Presented) A process for the preparation of a compound claim 16, which process comprises:

reacting an acid of the formula (2)

or an activated derivative thereof; with an amine of formula (3)

$$H_2N$$
 A
 $(R^1)_r$
 A
 $(R^3)_r$

and thereafter if necessary

- i) converting a compound of the formula (1) into another compound of the formula (1);
- ii) removing any protecting groups; or
- iii) forming a pharmaceutically acceptable salt or in vivo hydrolysable ester.